Clinical trials: Cellular Rejection
Kidney Transplant Rejection, Antibody-mediated Rejection
Donor-derived Cell-free DNA for Early Diagnosis of Antibody-mediated Rejection
Patients after kidney transplantation who develop donor-specific antibodies (DSA) are at high risk for antibody-mediated rejection (ABMR).
- Conditions
- Kidney Transplant Rejection, Antibody-mediated Rejection, Kidney Transplant Failure
- Trial name
- cfDNA-DSA (NCT04897438)
- Testing
- Kidney allograft biopsy depending on donor-derived cell-free DNA levels
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Charite University, Berlin, Germany
Kidney Transplantation, Acute Graft Rejection
Pre-formed Alloreactivity in Renal Transplant Recipients
This investigator-initiated study will analyse the role of pre-formed alloreactive T cells on acute rejection episodes and graft outcome in kidney transplant recipients after living donation.
- Trial name
- NCT02633826
- Where
- 13 sites in Germany
- Volunteers
- 190 people
- Sponsor
- Martina Sester
Renal Transplant Rejection
Belimumab Impacting Transplant Eligibility
This study is a prospective, open label, phase I/II pilot study.
- Trial name
- NCT02500251
- Testing
- belimumab, Bortezomib, Rituximab
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- E. Steve Woodle
Heart Transplant Rejection
Biomarkers for Diagnosis, Prognosis, and Targeted Therapy After Heart Transplantation
The objective of this prospective observational single center study is to investigate donor-derived cell-free DNA (ddcfDNA), peripheral blood platelet mRNA, peripheral blood extracellular vesicle mRNA, and peripheral blood…
- Trial name
- EMBIO (NCT06064123)
- Testing
- Cell-free DNA
- Where
- Finland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Kidney Transplant Rejection
Treatment of Antibody-Mediated Rejection (ABMR) With CarBel
The purpose of this study is to evaluate the safety of carfilzomib and belatacept, administered with steroids and maintenance immunosuppression, in kidney transplant recipients with donor-specific antibody (DSA)-associated graft…
- Trial name
- CarBel (NCT06918990)
- Testing
- Carfilzomib, Belatacept
- Where
- 11 sites in United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Organ Transplantation
Mesenchymal Stem Cells and Subclinical Rejection
The purpose of the study is to test the safety and feasibility of autologous mesenchymal stem cell therapy in HLA-DR mismatched patients with subclinical rejection and or an increase in IF?TA in the renal biopsy 4 weeks or 6…
- Trial name
- Measure (NCT00734396)
- Testing
- Mesenchymal stem cell infusion
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- Leiden University Medical Center
Renal Failure, Chronic, Renal Transplantation
Immunoregulatory Effects of Immunoglobulin Induction Therapy in Renal Transplant Recipients
The aim of this randomized prospective study in renal transplant recipients is to investigate immunological short and long-term effects of an IVIG induction therapy.
- Trial name
- NCT00176059
- Testing
- intravenous immunoglobulins (IVIG), kidney transplantation
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- University of Giessen
Autoimmune Diseases
Pilot Trial to Assess Effect of CNI Conversion of Efalizumab on T Reg Cells
The purpose of this pilot trial is to determine whether a conversion from calcineurin inhibitors (CNI) and mycophenolate mofetil (MMF) to a regimen consisting of efalizumab and sirolimus is associated with an increase in T…
- Trial name
- NCT00777400
- Testing
- Efalizumab
- Where
- United States
- Sponsor
- University of California, San Francisco
Chronic Lung Disease, Lung Transplant Rejection
Safety of Endobronchial Mesenchymal Stromal Cells in the Treatment of Chronic Lung Allograft Dysfunction
Lung transplantation is the only therapeutic alternative for more and more patients with respiratory diseases in their most advanced stages.
- Trial name
- ENDOSCLAD (NCT06514378)
- Testing
- Mesenchymal stem cells
- Where
- Spain
- Volunteers
- 12 people
- Sponsor
- Instituto De Investigación Sanitaria Puerta De Hierro-Segovia De Arana
Antibody-mediated Rejection, Kidney Transplantation
Incidence, Course and Outcome of ABMR in Kidney Transplantation
Rationale: Despite improved patient and graft survival in renal transplant recipients, still 20% of the patients reaches end-stage renal disease within 5 years after transplantation.
- Conditions
- Antibody-mediated Rejection, Kidney Transplantation, Immunosuppression
- Trial name
- PROCARE2 (NCT05140018)
- Testing
- Kidney Transplantation, Immunosuppression, Nephrectomy (kidney donation)
- Where
- 6 sites in Netherlands
- Volunteers
- 225 people
- Sponsor
- University Medical Center Groningen
Acute Cellular Graft Rejection, Liver Transplant Rejection
Budesonide for Immunosuppression After Liver Transplantation to Reduce Side Effects
Our hypothesis is that budesonide will provide effective hepatic ISP that will replace prednisone and allow lower systemic drug levels of FK, thus reducing the steroid- and calcineurin-associated complications often observed in…
- Trial name
- BILT (NCT03315052)
- Testing
- Budesonide, Tacrolimus（FK506）, Mycophenolate Mofetil
- Sponsor
- Montefiore Medical Center
Acute Cellular Graft Rejection, New Onset Diabetes After Transplant
Budesonide for Liver Transplant Immune Suppression
This is a pilot study that investigates the efficacy and safety of budesonide as an immune suppressing agent for liver transplant recipients in the early post-transplant period.
- Trial name
- NCT03304626
- Testing
- Budesonide 3Mg Capsule, Standard of Care Prednisone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Cincinnati
Kidney Transplant Failure and Rejection
Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated Rejection
Background: Long-term success of organ transplantation is limited by the inexorable loss of graft function due to rejection. Prevalent dogma defends that allograft rejection is exclusively mediated by the adaptive immune system…
- Trial name
- STARR (NCT03955172)
- Testing
- Everolimus
- Where
- France
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Lung Transplant Rejection, Lung Transplant Failure and Rejection
Comparison of Transbronchial Cryobiopsy and Forceps Biopsy in Lung Transplant Recipients
CLAD is defined as loss of lung function after other factors, particularly infections have been excluded. Readily accessible diagnostic procedures to detect acute cellular rejection at the earliest possible occasion is crucial…
- Trial name
- Kryo-LUTPL (NCT05006742)
- Testing
- CB study arm, FB-CB study arm
- Where
- Switzerland
- Volunteers
- 80 people
- Sponsor
- University of Zurich
Heart Transplant Failure and Rejection
Donor-Derived Cell-free DNA to DETect REjection in Cardiac Transplantation
The study objective is to demonstrate that rejection surveillance of heart transplant recipients with Prospera dd-cfDNA is non-inferior to rejection surveillance with endomyocardial biopsy and histology in the first…
- Trial name
- DETECT (NCT05081739)
- Testing
- Prospera Transplant Assessment, Endomyocardial biopsy
- Sponsor
- Natera, Inc.
Liver Transplant Rejection
Erythropoietin Therapy to Induce Regulatory T Cells in Liver Transplant Recipients
The goal of this proof-of-concept study is to EPO increases the frequency, stability and/or function of Tregs in liver transplant recipients.
- Trial name
- NCT05325073
- Testing
- Erythropoietin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Northwestern University
Heart Transplantation
Superiority Assessment of Donor-derived Cell-FreE DNA ( Deoxyribonucleic Acid) for Cardiac Allograft REjection Monitoring
Heart transplantation (HTx) remains the gold-standard treatment for patients with end-stage heart failure refractory to the medical management, offering the best survival and quality of life.
- Trial name
- SAFE-CARE (NCT07897526)
- Testing
- non-invasive strategy based of the analysis of circulating dd-cfDNA (AlloSeq cfDNA assay), control
- Volunteers
- 352 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Kidney Transplant Failure and Rejection
Study in Detection cfDNA for the Early-stage Diagnosis of Acute Rejection Post-renal Transplantation
Acute rejection (AR) is still one of the major complications after kidney transplantation. The current diagnosis measure for AR is primarily pathological puncture test and hematuria biomarker detection, yet due to their inferior…
- Trial name
- NCT03759535
- Testing
- Acute rejection
- Volunteers
- 60 people
- Sponsor
- RenJi Hospital
Cutaneous T-Cell Lymphoma, Graft Vs Host Disease
MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal Photochemotherapy
The objective of this study is to describe the type of cell death induced by extracorporeal photochemotherapy, depending on the cell type, using a panel of complementary analysis techniques.
- Conditions
- Cutaneous T-Cell Lymphoma, Graft Vs Host Disease, Graft Rejection
- Trial name
- MORPHEE (NCT05333367)
- Testing
- Samples collection
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Myelomonocytic Leukemia
Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders
This phase II trial studies the side effects and best dose of total-body irradiation when given together with fludarabine phosphate followed by a donor peripheral stem cell transplant in treating patients with myelodysplastic…
- Conditions
- Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Essential Thrombocythemia
- Trial name
- NCT00397813
- Testing
- Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Volunteers
- 77 people
- Sponsor
- Fred Hutchinson Cancer Center